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Background
Bone marrow mesenchymal stem cells support proliferation and differentiation of
hematopoietic progenitor cells in vitro. Since these cells constitute a rare subset of bone
marrow cells, mesenchymal stem cell preparations for clinical purposes require a prepara-
tive step of ex vivo multiplication. The aim of our study was to analyze the influence of
culture duration on mesenchymal stem cell supportive activity.
Design and Methods
Mesenchymal stem cells were expanded for up to ten passages. These cells  and CD34+
cells were seeded in cytokine-free co-cultures after which the phenotype, clonogenic
capacity and in vivo repopulating activity of harvested hematopoietic cells were assessed.
Results
Early passage mesenchymal stem cells supported hematopoietic progenitor cell expansion
and differentiation toward both B lymphoid and myeloid lineages. Late passage mes-
enchymal stem cells did not support hematopoietic progenitor cell and myeloid cell out-
growth but maintained B-cell supportive ability. In vitro maintenance of NOD/SCID
mouse repopulating cells cultured for 1 week in contact with mesenchymal stem cells was
effective until the fourth passage of the mesenchymal cells and declined thereafter. The
levels of engraftment of CD34+ cells in NOD/SCID mice was higher when these cells were
co-injected with early passage mesenchymal stem cells; however mesenchymal cells
expanded beyond nine passages were ineffective in promoting CD34+ cell engraftment.
Non-contact cultures indicated that mesenchymal stem cell supportive activity involved
diffusible factors. Among these, interleukins 6 and 8 contributed to the supportive activi-
ty of early passage mesenchymal stem cells but not to those of late passage cells. The phe-
notype, as well as fat, bone and cartilage differentiation capacity, of mesenchymal stem
cells did not change during their culture.
Conclusions
Extended culture of mesenchymal stem cells alters the ability of these cells to support
hematopoietic progenitor cells without causing concomitant changes in their phenotype
or differentiation capacity.
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progenitor cells of B lymphoid.
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Introduction
Umbilical cord blood is a valid alternative to bone mar-
row or mobilized peripheral blood as a source of
hematopoietic stem cells for clinical transplantation.
However the use of cord blood hematopoietic stem cells in
adult recipients is limited by the small numbers of cells pres-
ent in a single unit. Numerous studies have attempted to
expand hematopoietic stem cells ex vivo in cell cultures sup-
plemented with various combinations of hematopoietic
cytokines. Although large numbers of committed progeni-
tors can be obtained in a short period of 7 to 10 days, expan-
sion of true long-term repopulating cells has been difficult to
achieve. 
Mesenchymal stem cells (MSC) are non-hematopoietic
cells which can typically differentiate into adipocytic, osteo-
cytic and chondrocytic tissues. They may also participate in
the formation of hematopoietic stem cell niches.1,2 Indeed,
human MSC have been reported to secrete various
hematopoietic growth factors and support hematopoiesis in
vitro. In cytokine-supplemented cultures of CD34+ cells, the
expansion of nucleated cells as well as colony-forming cells
is greater when MSC are included in the culture than when
they are not.3 Differentiation of primitive progenitor cells
occurs mainly along the myeloid lineage, but B lymphoid
development has also been reported.4,5 In such co-culture
systems, repopulating cells, assayed in xenogeneic recipi-
ents, are maintained or modestly expanded.6,7 The relative
contributions of the cytokines and the feeder cells in the
overall supportive activity in these studies have not, howev-
er, been clearly determined. We have previously reported
that stromal cell derived factor 1 (SDF-1) may participate in
the cell cycle-promoting activity of MSC toward co-cultured
CD34+ cells.8
Another aspect of the hematopoiesis-supporting activity
of MSC lies in their ability to enhance bone marrow hom-
ing of co-injected hematopoietic stem and progenitor
cells.9,10 In this procedure, improved hematopoietic reconsti-
tution can be achieved without ex vivo expansion of
hematopoietic progenitors. In the NOD/SCID mouse
model, bone marrow homing is particularly enhanced when
limiting numbers of CD34+ cells are infused.11 The capacity
of MSC to improve engraftment of CD34+ cells can be
enhanced by stimulation with cytokines that increase
CXCR4 expression by MSC.12
Since they account for a very small fraction of bone mar-
row cells, preparations of MSC for clinical purposes require
a preliminary step of ex vivo multiplication. While consider-
able expansion of MSC is often needed to obtain large cell
doses starting from a bone marrow aspirate, the optimal
duration of MSC culture has not been defined. It has recent-
ly been reported that bone marrow homing of MSC
decreases with prolonged ex vivo culture.13 Whether other
properties of MSC relevant to their hematopoiesis-support-
ing activity are modified ex vivo remains to be established.14
In the present study, we analyzed the influence of culture
duration on MSC. The phenotype and differentiating capac-
ity of MSC preparations were assessed after up to ten pas-
sages. In parallel, the ability of MSC to support differentia-
tion and self-renewal of cord blood hematopoietic
stem/progenitor cells was assayed in cytokine-free co-cul-
tures. Enhancement of bone marrow homing was studied
by co-transplantation of MSC and unmanipulated cord
blood CD34+ cells into NOD/SCID mice. 
Design and Methods
Cell isolation and preparation
Human bone marrow samples were obtained from normal
adult volunteers. Mononuclear cells were isolated by centrifuga-
tion over Ficoll-PaqueTM Plus (GE Healthcare, Diegem, Belgium)
and washed in Dulbecco’s phosphate-buffered saline (DPBS;
Lonza, Verviers, Belgium). Cells were seeded at a density of 5×105
cells/cm2 in mesenchymal stem cell growth medium (MSCGM;
Lonza). MSCGM is a ready-to-use medium supplemented with
10% serum. Cultures were maintained in a humidified atmos-
phere at 37°C and 5% CO2. MSC were selected by plastic adher-
ence and elimination of non-adherent cells 24 h after cell seeding.
When cultures reached 90% confluence, cells were detached with
trypsin-EDTA solution (Lonza), and sub-cultured at 5×103
cells/cm2 for ten passages. All experiments assessing the influence
of passage number on the properties of MSC were done using
three independent MSC preparations, with the exception of the
secretion profile assays which were done with MSC from only
two donors. 
Human umbilical cord blood samples were obtained following
full-term vaginal delivery. All samples were processed within 24 h
after delivery. Mononuclear cells were isolated by centrifugation
over Ficoll-PaqueTM Plus and washed in DPBS. CD34+ cells were
purified using magnetic activated cell separation (MACS) CD34
isolation kits (Miltenyi Biotech, Gladbach, Germany). The purity
of the selected cells was always higher than 95%.
All material was acquired with informed consent and used
according to the guidelines established by the Ethical Committee
of the University of Liège.
Flow cytometric analysis of mesenchymal 
stem cell preparations
The following antibodies were used for phenotypic character-
ization of MSC: anti-CD13, anti-CD14 and anti-CD36 conjugat-
ed to fluorescein isothiocyanate (FITC), anti-CD11b, anti-
CD49a, anti-CD73, anti-CD90, anti-CD106, anti-CD146, anti-
CD271, and anti-SSEA4 conjugated to phycoerythrin (PE) (all
from BD Biosciences, Erembodegem, Belgium), PE-anti-CD105
(Serotec, Düsseldorf, Germany), PE-anti-STRO1 (Santa Cruz
Biotechnology, Heidelberg, Germany), anti-CD45 (BD
Biosciences), and anti-mouse IgG (Jackson ImmunoResearch,
Suffolk, England) conjugated to allophycocyanin (APC), and
purified anti-GD2 (BD Biosciences). Cells were incubated with
antibodies or isotype-matched control IgG for 30 min at 4°C in
the dark. Cells were washed in DPBS and fixed in DPBS 1%
formaldehyde (Vel, Leuven, Belgium). Data were acquired on a
BD FACSCanto II flow cytometer and analyzed using BD
FACSDiVa™ software. 
Mesenchymal stem cell differentiation assays
Fat, bone and cartilage differentiation assays were carried out as
described by Pittenger et al.15 and revealed by staining with oil red
O, alizarin red and toluidine blue, respectively. 
Mesenchymal stem cell secretion profile assays
At each passage, at 90% confluence, the medium was changed
and incubated for an additional 10 days. The MSC-conditioned
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medium was collected and frozen at –20°C for further analyses. In
some experiments, confluent MSC were stimulated with 10
ng/mL interleukin (IL)-1α every other day for 10 days. RayBio®
human cytokine antibody arrays (RayBiotech, Inc, Boechout,
Belgium) were used according to the provided protocols to ana-
lyze the presence of bone morphogenetic protein (BMP)-4, BMP-
7, Flt-3 ligand, granulocyte colony-stimulating factor (G-CSF),
granulocyte-monocyte colony-stimulating factor (GM-CSF), IL-10,
IL-15, IL-1α, IL-2, IL-3, IL-6, IL-7, IL-8, leukemia inhibitory factor
(LIF), L-selectin, stem cell factor (SCF), SDF-1, thrombopoietin
(TPO), vascular cell adhesion molecule (VCAM)-1, intracellular
adhesion molecule (ICAM)-1, matrix metalloprotease (MMP)-2,
MMP-3, MMP-10, MMP-13, and tissue inhibitor of metallopro-
tease (TIMP)-4 in conditioned medium. The concentrations of IL-
6 and IL-8 were measured using cytometric bead array kits (BD
Biosciences) according to the manufacturer’s recommendations.
Samples were analyzed in a BD FACSCanto II flow cytometer and
analyzed by using BD FCAP Array software (BD Biosciences).
Results are expressed as picograms per milliliter.
Long-term cultures of CD34+ cells and mesenchymal
stem cells
Five thousand CD34+ cells were plated either in contact with
confluent MSC or in transwells seeded with MSC. Cultures were
maintained for 3 weeks. Thereafter, the persistence of primitive
progenitors was assessed by transferring cells into a semi-solid
medium to allow development of secondary hematopoietic
colonies. As a control, uncultured CD34+ cells were transferred
directly into the semi-solid medium. The long-term culture medi-
um consisted of α-MEM supplemented with 8% horse serum, 8%
fetal bovine serum, 0.2 mM glutamine, 100 U/mL penicillin and
100 µg/mL streptomycin (all from Lonza), 0.2 mM inositol (Sigma-
Aldrich), and 0.1 mM 2-mercaptoethanol (Invitrogen, Merelbeke,
Belgium). Cultures were maintained at 37°C in 5% CO2 with
weekly changes of half the medium. In some experiments, cul-
tures were supplemented every other day with 1 µg/mL of anti-
IL6 or anti-IL8 function-blocking antibodies (R&D, Abingdon,
UK). After 3 weeks, cultures were trypsinized. First, a third of the
cell suspension was transferred in duplicate progenitor assays into
a semi-solid medium consisting of MethoCult® GF+ H4435 (Stem
Cell Technologies). After an additional 2 weeks of incubation at
37°C secondary colony-forming cells were scored. The remaining
two-thirds of the cells were harvested for FACS analysis. Absolute
numbers of CD34+, CD10+, CD19+, CD11b+ and CD33+ cells
grown in cultures were determined using TruCount tubes (BD
Biosciences). APC-conjugated anti-CD34, PE-Cy7-conjugated
anti-CD10, APC-Cy7-conjugated anti-CD19, PE-conjugated anti-
CD11b and peridin chlorophyll-cyanin 5.5-conjugated anti-CD33
(all from BD Biosciences) were used. Cells were incubated with
antibodies or isotype-matched control IgG for 30 min at 4°C in the
dark. Cells were washed in DPBS and fixed in DPBS 1% formalde-
hyde. Data were acquired on a BD FACSCanto II flow cytometer
and analyzed using BD FACSDiVa™ software.
Assessment of B-cell maturation
The stage of maturation of B cells generated after 3 weeks of
co-culture in contact with MSC was assessed by flow cytometry
analysis and real-time quantitative polymerase chain reaction
(PCR) analysis of B-specific transcripts. For FACS analysis, the
following antibodies were used: FITC-conjugated anti-kappa,
FITC-conjugated anti-IgM, PE-conjugated anti-lambda, PE-con-
jugated anti-CD79a (all from BD Biosciences). After cell fixation
and permeabilization using a BD Cytofix/Cytoperm™
Fixation/Permeabilization kit, cells were incubated with anti-
bodies or isotype-matched control IgG for 30 min at 4°C in the
dark. Data were acquired on a BD FACSCanto II flow cytome-
ter and analyzed using BD FACSDiVa™ software.
For real-time quantitative PCR analysis, RNA was isolated using
an RNeasy Blood & Tissue Kit (Qiagen, KJ Venlo, the
Netherlands). The concentration and purity of the RNA were esti-
mated by optical density measurements. To avoid genomic DNA
contamination, RNA was treated with RNase-free DNaseI
(Fementas GMBH, St.Leon-Rot, Germany) at 37°C for 30 min.
cDNA synthesis was performed using a RevertAid™ H Minus
First Strand cDNA Synthesis Kit (Fermentas). cDNA was analyzed
by real-time PCR, with amplification performed using the ABI
Prism 7700 sequence detection system (Applied Biosystems,
Lennik, Belgium). A 20 µL reaction mixture containing 10 µL of
Power SYBR® Green PCR master mix (Applied Biosystems) and
cDNA template and forward and reverse primers was used. Target
genes were EBF (forward primer: GATACGGCTCTGCCGCAAT,
reverse primer: CAGCTGAGCCGTTGAGGAA), PAX5 (forward
primer: TGGAGGATCCAAACCAAAGG, reverse primer:
GGCAAACATGGTGGGATTTT), RAG1 (forward primer: CAT-
CAAGCCAACCTTCGACAT, reverse primer: CAGGACCATG-
GACTGGATATCTC), TdT (forward primer: TTGCCCT-
GTTGGGATGGA, reverse primer: TCCGCTCATGTGTG-
GCATAG), and VPREB (forward primer: GACATCGGTGTG-
TACAGCGTCTA, reverse primer: TGGCTCTTGTCTGATTGT-
GAGAA). The reference gene was β2-microglobulin (forward
primer: GAGTATGCCTGCCGTGTG, reverse primer: AATC-
CAAATGCGGCATCT). Relative quantities of target genes were
calculated using the relative standard curve method recommend-
ed by Applied Biosystems.
Transplantation of human cells into NOD/SCID mice
Two-month old NOD/SCID mice were sublethally irradiated
with 300 cGy from a 137Cs source (GammaCell 40, Nordion,
Ontario, Canada). Four hours before injection, 10 days and 21
days after engraftment, the mice received 20 µL of anti-asialo
GM1 antiserum (Wako Chemicals GmbH, Neuss, Germany) by
intraperitoneal injection. The mice were injected with 1.5×105
CD34+ uncultured cells or the expansion product of 1.5×105 CD34+
cells co-cultured for 1 week in contact with confluent MSC har-
vested at passage (P)1 to P10 in long-term culture medium. Other
mice were transplanted with the expansion product of 1.5×105
CD34+ cells co-cultured for 1 week in transwells seeded with con-
fluent MSC. For co-transplantation experiments, mice were
infused with 1.5×105 uncultured CD34+ cells and 1.5×105 MSC har-
vested at P1 to P10. Cells were infused by intravenous tail injec-
tion. After 6 weeks, the mice were killed by cervical dislocation
and bone marrow cells were harvested from the femora and tibi-
ae by flushing the bones with Iscove’s modified Dulbecco’s medi-
um (Lonza) with 10% fetal bovine serum. Mononuclear low-den-
sity cells were isolated by centrifugation over Ficoll-PaqueTM Plus,
washed and resuspended in the same medium with 10% fetal
bovine serum. In order to assess engraftment, bone marrow cells
from recipient mice were pelleted and incubated with various
mouse anti-human monoclonals for 30 min at 4°C in the dark.
APC-conjugated anti-human CD45, FITC-conjugated anti-human
CD33 and PE-conjugated anti-human CD19 (all from BD
Biosciences) were used. Cells were washed in DPBS and fixed in
DPBS 1% formaldehyde. Data were acquired on a BD FACSCanto
II flow cytometer and analyzed using BD FACSDiVa™ software.
Hematopoiesis support by MSC
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Positive cells were identified by comparison with isotypic con-
trols. All experiments were conducted in accordance with the rec-
ommendations of the Animal Ethics Committee of the University
of Liège.
Homing of mesenchymal stem cells
Two-month old NOD/SCID mice were sublethally irradiated
with 300 cGy from a 137Cs source. Four hours before injection, 10
days and 21 days after engraftment, the mice received 20 µL of
anti asialo GM1 antiserum by intraperitoneal injection. Mice
received 2×105 MSC from P3 or P7 by intravenous tail injection.
After 24 h and 5 weeks, mice were killed by cervical dislocation
and blood, bone marrow, spleen, lung, liver, kidney and small
intestines were harvested and frozen. Genomic DNA was isolated
from the mouse tissues using a DNeasy Blood & Tissue Kit
(Qiagen). The concentration and purity of the DNA were estimat-
ed by optical density measurements. DNA was analyzed by real-
time PCR, with amplification performed using the ABI Prism 7700
sequence detection system. A 20 µL reaction mixture containing
10 µL of Power SYBR® Green PCR master mix and 100 ng of
DNA template and forward and reverse primers was used. The
target gene was human albumin, the forward primer was
TGAAACATACGTTCCCAAAGAGTTT, and the reverse primer
was CTCTCCTTCTCAGAAAGTGTGCATAT. The reference
gene was murine β-actin, the forward primer was CCTGTG-
GCATCCATGAAACTAC, and the reverse primer was CACTGT
GTTGGCATAGAGGTCTTT. The relative quantity of human
albumin gene was calculated using the comparative Ct method. A
validation experiment was carried out to confirm that efficiency of
amplification of the target and reference genes were similar. The
absolute value of the slope of log input amount versus Ct was less
than 0.1, as recommended by the manufacturer.
Statistical analysis
Results are reported as mean ± standard error of the mean
(SEM). Comparisons were made using two-tailed Student’s t tests,
Mann-Whitney tests or Z-tests with SigmaPlot and SigmaStat
software (SPSS, Richmond, CA, USA).
Results
Mesenchymal stem cell expansion and characterization
of the mesenchymal stem cell preparations
MSC were purified by plastic adhesion and expanded in
MSCGM. Cells were passaged every 10 days. There were
two to three doublings at each passage (Online
Supplementary Figure S1). MSC proliferated for at least ten
passages. Cells were harvested at each passage and their
phenotype and differentiation potential assessed.
As early as the second passage, cells displayed a charac-
teristic mesenchymal phenotype, being negative for
CD11b, CD14, CD36 and CD45, weakly positive (mean
channel fluorescence ratio, MCFR 1.5 to 3.5) for CD49a,
CD105, CD106 and CD146 antigens, positive (MCFR 3.5
to 9) for CD13 and CD73, and strongly positive (MCFR >
25) for CD90 and GD2 antigens. Cells did not express
antigens previously reported on MSC such as CD271,
SSEA4 and STRO-1 antigens16-18 (Online Supplementary
Figure S1). There were no consistent changes in phenotype
for at least ten passages.
Differentiation into fat, bone and cartilage was assessed
by transferring MSC into specific induction media.15 Lipid
vacuoles, calcium deposits and chondrogenic differentia-
tion were revealed with oil red O, alizarin red, and tolui-
dine blue, respectively. The ability to differentiate into
these three tissues was present in every MSC preparation
tested, up to P10 (data not shown). All MSC preparations
used to assess the ability of these cells to support
hematopoiesis, as described below, were confirmed to
have the same phenotype and differentiation capacity.
Cytokine secretion profile
The presence of various hematopoietic cytokines, adhe-
sion molecules and metalloproteases in MSC-conditioned
medium was assayed at several passages by cytokine
arrays (detection limit: 4-25 pg/mL). In baseline conditions
IL-6, IL-8, SDF-1, VCAM-1, ICAM-1, MMP-2, MMP-3,
MMP-13 and TIMP-4 were detected in MSC-conditioned
medium. When MSC were stimulated with IL1-α, an
additional secretion of GM-CSF, LIF and MMP-10 was
observed. Both the baseline and IL1α-stimulated secretion
profiles were maintained up to P10 without variations in
the nature of molecules detected. Next, the expression of
IL-6 and IL-8, the two most abundantly secreted mole-
cules, was quantified by flow cytometric bead arrays. We
observed that the level of IL-6 secretion was 4.95±1.27
ng/mL after P1-3, increased to 24.0±8.5 after P4-6
(P<0.001) and was maintained until P10. Conversely, IL-8
secretion decreased progressively from 8.1±3.6 ng/mL
after up to P3, to 4.7±1.4 ng/mL after P4-6, 4.3±0.7 at P7-
8 and 2.3±0.6 ng/mL after P9 or 10 (P<0.01 versus P1-3;
Online Supplementary Figure S1).
Hematopoiesis supporting ability of mesenchymal stem
cells in long-term cultures
The ability of MSC to support hematopoiesis in vitro
was evaluated by establishing long-term cultures in con-
tact and non-contact conditions. In contact conditions, the
output of secondary colony-forming cells was higher after
co-culture with P1 MSC and lower after co-culture with
MSC harvested after four or more passages, relative to
uncultured cells (P<0.05; Figure 1A). The number of sec-
ondary colony-forming cells was higher in non-contact
conditions (Figure 1B) than in contact conditions for all the
MSC preparations tested. A significant decline of
hematopoiesis supporting ability with the number of pas-
sages was also noted in non-contact conditions (P<0.05). 
The phenotype of hematopoietic cells grown in cultures
with MSC was established. The expression of CD34,
CD33, CD11b, CD19 and CD10 was tested on cells har-
vested after 3 weeks in contact and non-contact condi-
tions. Flow cytometric analysis was carried out in tubes
containing a defined number of latex beads, in order to
measure absolute numbers of cells with a given pheno-
type (Figure 2A). In contact conditions (Figure 2B), an
expansion of CD34+ cells was noted after culture with P2
MSC. CD34+ cell expansion was less substantial after cul-
ture in contact with MSC harvested after four or more
passages (P>0.05). Myeloid cells expressing CD33 and/or
CD11b also increased substantially after culture with P2
MSC, and much less with MSC of further passages
(P<0.05). In contrast, lymphoid cells expressing CD19
and/or CD10 were maintained or expanded with P2 MSC
A. Briquet et al.
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as well as with P4 and P7 MSC. In non-contact conditions
(Figure 2C), CD34+ cells persisted after culture with P2, P4
or P7 MSC without net proliferation. Mature myeloid cells
virtually disappeared after culture with P7 MSC (P<0.05),
while lymphoid cell numbers were higher after culture
with P7 MSC than with P2 or P4 MSC (P<0.05). Thus, in
both contact and non-contact conditions, MSC support
for myeloid progenitors decreased with the number of
passages while B lymphoid support was maintained or
even increased in late passage MSC. 
In vitro B-cell maturation of human CD34+ cells has been
reported previously to be dependent on co-culture with
specific murine stromal cell lines, such as MS-5 and
S17.19,20 This prompted us to investigate whether recapitu-
lation of B-cell ontogeny could be obtained with human
MSC. Phenotypic and molecular analyses were carried out
to define the stage of maturation stage of outgrown B
cells. FACS analysis of cultured CD34+ cells showed the
expression of cCD79a, cytoplasmic κ and λ light chains as
well as cytoplasmic µ heavy chain on more than 30% of
the cells. In comparison, less than 4% of uncultured
CD34+ expressed the same B-cell markers (Figure 3A).
Membrane expression of κ and λ light chains as well as
complete IgM was demonstrated on cultured CD34+ cells
but not on native CD34+ cells (Figure 3B). Real-time quan-
titative PCR analysis detected the expression of B-cell-spe-
cific transcripts, such as TdT, RAG, VpreB, EBF and Pax-5,
in cells harvested after 3 weeks of co-culture with MSC,
but not in uncultured CD34+ cells (Figure 3C). This indi-
cates induction of the B-cell transcriptional program fol-
lowing contact with MSC. Thus, CD34+ cells undergo B-
cell differentiation up to the stage of immature IgM+ B
cells when in contact with human MSC, similarly to pre-
viously reported findings in models using murine stromal
cell lines.
Hematopoiesis support by MSC
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Figure 1. Supportive activity of MSC in contact and non-contact
conditions. (A) Absolute number of colony-forming cells after 3
weeks of co-culture initiated with 5000 cord blood CD34+ cells in
contact with MSC harvested at indicated passage (P) or in 5000
uncultured CD34+ cells (U). (B) Cultures were conducted in non-con-
tact conditions. *P<0.05, **P<0.01, ***P<0.005, ****P<0.001
versus uncultured CD34+ cells, n≥4.
Figure 2. Support of myeloid and lymphoid progenitors by MSC.
Absolute numbers of CD34+, CD19+, CD10+, CD33+ and CD11b+ cells
grown after 3 weeks in long-term cultures with MSC harvested at
indicated passage (P) or uncultured CD34+ cells (U), n=3. (A)
Representative data of flow cytometric analysis. (B) Cultures were
conducted in contact with MSC. (C) Cultures were conducted in non-
contact conditions. *P<0.05, **P<0.01, ***P<0.005, ****P<0.001
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Maintenance of SCID repopulating cells in co-culture
with mesenchymal stem cells
Two-month old NOD/SCID mice sublethally irradiated
with 300 cGy were used in these experiments. Cells were
transplanted by intravenous tail injection. After 6 weeks
the mice were killed and bone marrow cells were harvest-
ed from femora and tibiae. Human chimerism was ana-
lyzed by flow cytometry (Figure 4A). Mice were consid-
ered positive when at least ten cells co-expressing hCD45
and either hCD19 or hCD33 were detected in 100×103
mouse bone marrow cells (detection limit: 0.01%).
First, mice received 1.5×105 CD34+ uncultured cells or
the expansion product of 1.5×103 CD34+ cells co-cultured
for 1 week with confluent MSC harvested at P1 to P10
(Figure 4C, Table 1). Human CD45+/CD19+ or CD33+ cells
were detected in the bone marrow of 50% of mice trans-
planted with uncultured CD34+ cells, with an average
chimerism of 1.38±0.53%. After co-culture with early pas-
sage MSC, more than 50% of the mice were positive (P1-
P2: 70%, P3-P4: 68%, P>0.05). However, there was no sig-
nificant difference in the percentage of engrafted human
cells between mice transplanted with uncultured CD34+
cells and mice receiving CD34+ cells co-cultured with early
passage MSC (up to P4). After co-culture with late passage
MSC (P5 to P10) only 10% of the mice showed reconsti-
tution and the percentage of engrafted human cells was
very low, at 0.02% (P<0.005 compared to co-culture with
P1-P4 MSC). Thus maintenance of repopulating cells was
higher in contact with early passage MSC than with late
passage MSC. 
We next asked whether prolonged co-culture of CD34+
cells in contact with MSC could increase repopulating
activity. Mice were injected with the product of 1.5×105
CD34+ cells co-cultured with confluent P2 MSC for 2
weeks and 3 weeks. After the 2-week culture, no bone
marrow repopulation was observed (human chimerism
A. Briquet et al.
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Figure 3. B-cell generation stimulated by MSC.
Flow cytometric analysis of cells grown after 3
weeks in long-term cultures with MSC (right) or
uncultured CD34+ cells (left). (A) Intracellular
staining. (B) Surface staining. Representative
experiment out of three. (C) Relative quantitation
of mRNA for B specific transcripts (EBF, Pax-5,
TdT, VpreB and RAG) in uncultured CD34+ cells
(black bars) or in cells grown after 3 weeks of co-
culture with MSC (white bars). *P<0.05,
**P<0.005, ***P<0.001 versus uncultured
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<0.01% in 5/5 recipients), whereas after the 3-week cul-
ture, human engraftment was 0.09±0.04% (n=5) but con-
sisted exclusively of CD19+ B cells without myeloid
engraftment. Thus, co-culture of CD34+ cells in contact
with MSC allows maintenance but not expansion of
repopulating cells.
Next, mice were transplanted with the expansion prod-
uct of 1.5×105 CD34+ cells co-cultured for 1 week in non-
contact conditions, in transwells seeded with confluent P4
MSC. An additional group of mice was injected with
CD34+ cells simply incubated for 1 week in P4 MSC-con-
ditioned medium. A third group was transplanted with
CD34+ cells kept for 1 week in unconditioned medium
(Figure 4D, Table 1). The percentages of positive mice
were similar when the animals were transplanted with
CD34+ cells cultured in non-contact conditions (72%) and
in conditioned medium (80%), as well as in contact condi-
tions (68%). There was no significant difference in the
percentage of chimeric human cells between mice trans-
planted with CD34+ cells cultured in contact with MSC
(P3-P4: 0.63±0.21%) and with MSC conditioned medium
(0.56±0.32%). The percentage of human cells was slightly
higher after transplantation of the expansion product of
CD34+ cells co-cultured in transwells (4.66±2.68%) but
the difference did not reach statistical significance.
Transplantation of mice with CD34+ cells cultured in
unconditioned medium yielded only one positive mouse
out of five, with 0.17% human chimerism. 
Next, we investigated the potential activity of MSC in
improving bone marrow engraftment of uncultured
CD34+ cells. For this purpose, 1.5×105 fresh cord blood
CD34+ cells were directly co-injected with 1.5×105 MSC
harvested after P1 to P10 (Figure 4E, Table 1). With this
strategy, more than 50% of the mice showed human
hematopoietic reconstitution. Compared to engraftment
following infusion of CD34+ cells only, the percentage of
engrafted human cells was dramatically increased after co-
injection with MSC harvested at P1 to P8 (P<0.006).
Conversely, MSC harvested at P9 and 10 were ineffective
in providing enhanced engraftment of uncultured CD34+
cells (P<0.05).
Regulation of the hematopoiesis-supporting activity 
of mesenchymal stem cells by interleukins 6 and 8
We attempted to define critical cytokines contributing
to the pro-hematopoietic activity of MSC. CD34+ cells
were cultured in contact with MSC in medium supple-
mented with antibodies neutralizing IL-6 or IL-8, or with
control IgG. First long-term cultures were established with
P2 or P7 MSC as feeder cells. A decrease of CD34+
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Figure 4. Human repopu-
lating cells in NOD/SCID
mice. (A) Representative
flow cytometric analysis of
recipient mice bone mar-
row mononuclear cells. (B)
Experimental design. (C)
Mice received uncultured
CD34+ cells (U) or the
expansion product of
CD34+ cells co-cultured for
1 week in contact with
confluent MSC harvested
at P1 to P10. *P<0.05
versus other passages.
Each open symbol repre-
sents one mouse. Solid
symbols are the mean ±
SEM. (D) Mice received
the expansion product of
CD34+ cells co-cultured in
contact with P4 MSC, in
non-contact conditions in
transwell seeded with P4
MSC, in P4 MSC-condi-
tioned medium (MSC-CM)
or in unconditioned medi-
um (UM). *P<0.05 versus
UM (E) Uncultured CD34+
cells were injected alone
(U) or co-injected with
MSC harvested at P1 to
P10 without prior culture.
*P<0.01 versus other pas-
sages; **P<0.01 versus
co-injection with MSC of
passages P1-3, P4-6 and
P7-8. The detection limit
of human cell engraft-
ment was set at 0.01% of
recipient mice bone mar-
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(P<0.05, Figure 5A), CD33+ (P<0.05, Figure 5B) and CD19+
(P>0.005, Figure 5C) outgrown cells was observed after
neutralization of IL-6 or IL-8 in 3-week cultures in contact
with P2 MSC. Conversely, when cultures were set on P7
MSC, IL-6 neutralization had no effect while increases of
CD34+ and CD19+ cell outgrowth were noted after inhibi-
tion of IL-8 (Figure 5A, B and C for CD34+ cells, CD33+
cells and CD19+ cells, respectively). 
Next, NOD/SCID mice were transplanted with CD34+
cells cultured for 1 week with P2 MSC, in medium supple-
mented with IL-6 or IL-8 function-blocking antibodies. A
slight but statistically significant decrease in repopulating
activity was noted after IL-8 neutralization, while IL-6
neutralization had no effect (Figure 5D). Thus, in contact
with early passage (P2) MSC, both IL-6 and IL-8 con-
tribute to in vitro differentiation of myeloid and lymphoid
cells, while only IL-8 is involved in the maintenance of
repopulating cells. Neither IL-6 nor IL-8 mediated
hematopoietic support in contact with late passage (P7)
MSC.
Homing of mesenchymal stem cells
Finally, the homing capacity of MSC in several tissues
was tested after P3 and P7. NOD/SCID mice sublethally
irradiated with 300 cGy received 2×05 MSC from P3 or P7
by intravenous tail injection. After 24 hours and 5 weeks,
mice were killed and blood, bone marrow, spleen, lung,
liver, kidney and small intestine were harvested for DNA
analysis by real-time PCR of human albumin. Twenty-
A. Briquet et al.
54 haematologica | 2010; 95(1)
Figure 5. Regulation of MSC supportive activity by IL-6 and IL-8.
Outgrowth of CD34+ (A), CD33+ (B) and CD19+ (C) cells after 3 weeks
in long-term cultures supplemented with anti-human IL-8, anti-
human IL-6 or control IgG, n=3. Results are expressed as fold
increase relative to input cells. *P<0.05, **P<0.005 versus cultures
supplemented with control IgG. (D) Analysis of human cells in the
bone marrow of recipient NOD/SCID mice that received the expan-
sion product of CD34+ cells co-cultured for 1 week with confluent P2
MSC. Cultures were supplemented with anti-human IL-6, anti-human
IL-8 or control IgG. Each open symbol represents one mouse, closed
symbols are mean ± SEM. *P<0.05 versus IgG control.
Table 1. Recovery of repopulating cells after co-culture or co-injection with
MSC.
Type of cells Passage Number Percent
in transplant number of of positive human cells in
MSC used mice/total recipient bone 
number of marrow
injected mice (%) (mean±SEM)
Uncultured CD34+ cells only − 12/24 (50) 1.38±0.5
CD34+ cells cultured P1-P2 19/27 (70) 2.34±0.83a
in contact with MSC
P3-P4 15/22 (68) 0.63±0.21a
P5-P10 1/10 (10) 0.02±0.00
CD34+ cells cultured P4 18/25 (72) 4.66±2.68b
without contact with MSC
CD34+ cells cultured P4 4/5 (80) 0.56±0.32
with MSC-conditioned medium
CD34+ cells cultured − 1/5 (20) 0.17±0.00
with unconditioned medium
Uncultured CD34+ cells P1-P3 7/9 (78) 7.21±1.94c,d
co-injected with MSC
P4-P6 14/15 (93)e 6.51±1.18c,d
P7-P8 8/9 (89) 10.48±3.46c,d
P9-P10 8/10 (80) 1.25±0.43
NOD/SCID mice were transplanted with 1.5x105 uncultured CD34+ cells, the expansion
equivalent of 1.5x105 CD34+ cells cultured in the indicated conditions or uncultured
1.5x105 CD34+ cells co-injected with MSC.MSC preparations of defined passages were
used as indicated.The proportion of positive mice and the mean % human cells in positive
mice is given for each condition,at 6 weeks post-transplantation. aP<0.05 versus P5-P10,
Mann-Whitney tests. bP<0.05 versus cultured with unconditioned medium,Mann-Whitney
tests. cP<0.01 versus P9-P10,Mann-Whitney tests; dP<0.01 versus uncultured CD34+ cells





















































































IgG anti-IL8 anti-IL6 IgG anti-IL8 anti-IL6
IgG anti-IL8 anti-IL6 IgG anti-IL8 anti-IL6
IgG anti-IL8 anti-IL6 IgG anti-IL8 anti-IL6
four hours after injection of P3 MSC, bone marrow, small
intestine, liver and lung tested positive for human albumin
in at least one mouse in each group of four (Online
Supplementary Table S1). Spleen and kidney were negative
in all mice. All mice tested positive in the lungs and at least
10-fold more MSC were detected in the lungs as com-
pared to in other tissues. After 5 weeks bone marrow was
positive in all mice, whereas the other organs were all neg-
ative. Late passage (P7) MSC showed a similar tissue dis-
tribution. Overall, these results suggest that MSC, irre-
spective of passage number, were first trapped in the lungs
before reaching other organs such as small intestine or
bone marrow. Only in the bone marrow could MSC sur-
vive up to 5 weeks.
Discussion 
Recent clinical trials indicate that MSC might be useful to
prevent and/or treat graft-versus-host disease and promote
donor cell engraftment after hematopoietic stem cell trans-
plantation.21,22 The procedures used to prepare MSC for clin-
ical applications are based on enrichment of MSC present in
bone marrow mononuclear cells by plastic adherence, fol-
lowed by ex vivo expansion in selected serum-containing
media.23 The duration of the ex vivo expansion step is high-
ly variable and depends on the ratio between the number of
MSC in the initial bone marrow inoculum and the target
number of MSC to infuse to the patient, i.e., on the number
of doublings. It has been described that the capacity of MSC
to engraft in recipient bone marrow declines with increasing
passage number.13 Whether the hematopoiesis-supporting
activity of MSC is modified with culture duration had not
been studied before.
In the present study, cultures of cord blood CD34+ cells
were set up in contact with feeder cells consisting of MSC
harvested after two to ten passages. Cells were plated in the
absence of exogenous cytokines which might otherwise
blunt changes in the hematopoiesis-supporting properties of
MSC. Our main results indicate a progressive decline in the
output of colony-forming cells by CD34+ cells cultured with
MSC of increasing passage. Likewise, the outgrowth of dif-
ferentiated myeloid CD33+ and CD11b+ cells was reduced
when MSC of late passages were used. In addition, ex vivo
maintenance of SCID repopulating cells (SRC) was reduced
when MSC had already undergone more than five passages,
which represents approximately 10 to 12 doublings. In con-
trast, MSC support of lymphoid CD19+ and CD10+ cell out-
growth was not dependent on the number of passages that
the mesenchymal cells had undergone. When the engraft-
ment-promoting activity of MSC was assayed by co-trans-
plantation with uncultured CD34+ cells, it was also observed
that late passage MSC (>9 passages or 25 doublings) were
inferior compared to early passage MSC. 
A detailed characterization of MSC preparations revealed
only minor changes with passage number. The phenotype
of MSC preparations was stable up until P10, as was the rate
of doublings. Differentiation into fat, bone and cartilage was
also conserved. The types of cytokines, adhesion molecules
and matrix proteases detected in MSC-conditioned medium
were similar in all tested passages. However, quantitative
measurements of the two most abundant cytokines pro-
duced by MSC, i.e. IL-6 and IL-8, revealed a progressive
decline of IL-8 secretion during culture while IL-6 secretion
was increased. Inhibition experiments showed that both
cytokines contributed to the outgrowth of CD34+, CD19+
and CD33+ cells in cultures supported by low passage MSC,
but not by late passage MSC. Interestingly, inhibition of IL-
8, but not of IL-6, was also associated with decreased main-
tenance of SRC in cultures with P2 MSC. This suggests that
the level of IL-8 may represent a surrogate marker of the
hematopoiesis-supporting activity of MSC, while high lev-
els of IL-6, as observed in medium conditioned with late
passage MSC, do not contribute to better support of
hematopoietic cells. The mechanism by which IL-8 pro-
motes recovery of SRC from in vitro cultures remains to be
determined. IL-8 has been reported to stimulate metastasis
and angiogenesis in various tumor models.24 Our hypothesis
is that IL-8 enhances engraftment of repopulating cells by
increasing expression of metalloprotease MMP-2 and conse-
quently migration and infiltration within the bone mar-
row.25
Our data also indicate the influence of direct contact
between MSC and CD34+ cells in co-cultures. Cultures of
CD34+ cells and MSC separated in transwells by a semi-per-
meable filter did not reduce the output of colony-forming
cells and SRC, in comparison with output of contact cul-
tures. In contrast, outgrowth of differentiated myeloid and
lymphoid cells was massively reduced in non-contact condi-
tions. Thus, direct contact with MSC appears to be impor-
tant for proliferation, late commitment and differentiation
of hematopoietic cells but at the expense of a depletion of
the progenitor cell compartment. From a practical stand-
point for the clinical use of CD34+ cells/MSC co-cultures,
non-contact conditions might allow for effective colony-
forming cell expansion while limiting the generation of
mature cells.
Our study also reveals the strong pro-lymphopoietic
activity of MSC. In vitro B-cell generation was previously
reported to depend on specific murine stromal cell lines.20 In
our study and as recently reported by Ichii et al.,4 MSC were
able to support the production of B-cell progenitors and
immature IgM+ B cells, in serum-containing medium, in the
absence of exogenous cytokines. We extend these findings
by showing, by quantitative PCR analysis, the expression of
TdT, RAG-1, VpreB, Pax-5 and EBF in outgrown B cells, but
not in input CD34+ cells. Thus, this co-culture system reca-
pitulates B-cell ontogeny up to immature B cells and could
be further used to delineate extrinsic signals implicated in
human B-cell development. The pro-lymphopoietic activity
of MSC is not affected by prolonged ex vivo culture, up to 30
doublings. The generation of B cells by co-culture of CD34+
cells and MSC opens up new therapeutic possibilities.
Whether MSC co-transplantation in patients undergoing
hematopoietic stem cell transplantation can be used to has-
ten B-cell regeneration could be studied in future clinical tri-
als. Enhancement of in vitro maturation of CD34+ cells to B
lymphocytes by MSC could also have implications in the
design of adoptive immunotherapy procedures.26
In conclusion, our study shows that prolonged ex vivo cul-
ture of bone marrow MSC is associated with decreased sup-
port of repopulating stem cells and myeloid progenitors,
while the supportive activity toward B lymphoid progeni-
tors is maintained. These changes are not accompanied by
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alterations in the phenotype or the differentiating capacity
of MSC. An important implication is that current quality
control procedures used in clinical cell therapy laboratories
and based on phenotype analysis do not accurately reflect
the biological properties of MSC preparations. Our data also
imply that MSC prepared for clinical trials should be pas-
saged as little as necessary.
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